Navigation Links
NCCN Holds Oncology Research Best Practices Conference
Date:9/14/2009

active and meet the needs of a multidisciplinary audience including oncology researchers, research nurses, Institutional Review Board (IRB) professionals, research administrators, academics, ethicists, government regulators, and industry sponsors on best practices in oncology research.

NCCN recognizes the importance of investing in clinical trials, which can result in changes in the standard of care and improved patient outcomes. Through the NCCN Oncology Research Program (ORP), more than $20 million of funding has been obtained to support investigator-initiated trials at NCCN Member Institutions to explore new avenues of clinical investigation and answer important scientific questions. The NCCN ORP recently launched a new platform, the Drug Development Research Grant Model that provides a mechanism for research on drugs in early stages of development.

Complete program details and online registration for the NCCN Oncology Research Best Practices Conference(TM) are available at NCCN.org.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve
'/>"/>

SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives
2. Fauquier Health System Holds a Food Show with a Twist Long Term Care Patients Hold the Judges Pen as Vendors Vie for Approval
3. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
4. Epilepsy Drug Holds Promise as Treatment for Alcoholism
5. Sunday, October 14, MSPP holds Sixth Annual Lucero Memorial Run and Latino Leadership Breakfast
6. Alzheimers Foundation of America Holds Fifth Annual National Memory Screening Day
7. European Patent Office Upholds Verathons IP Against Aircraft Medical Challenge
8. University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome
9. Go Red For Women Holds Nationwide Casting Call to Find the Heart of Go Red
10. Fruit fly phlebotomy holds neuroscience promise
11. American Association for Dental Research holds 37th annual meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ce"reform"isamoraloutrage ,, WASHINGTON,Nov.2...ovedforwardtobeginthedebateontheirhealthcare"refor...nggrassrootssenioradvocacygroup,iscallingonallofAm...ivecutstoMedicare.RetireSafePresidentThairPhillips...axes,abortion,andimmigration,whilethesimple,uncomp...
(Date:11/23/2009)...,, WHAT: ,, TheBerylInstitute, theresearc...sleadinghealthcareexclusivecallcenter,issponsoring...ygenerationwithapositivecustomerserviceexperience....binarwillsupplementHowe,sJune2009whitepaper,"Custo...sseshowconsumerswillultimatelytransformhealthcared...
(Date:11/23/2009)...re/--CortivaInstituteTucsonwillhostanIntroductiont...theschool,s6390EastBroadwayBlvd.location,whichwill...icebasicmassagestrokes. ,, "Massagetherapyisagr...longwithit,"saidJoannMcMaster,presidentofCortivaIn...or,s2009-2010OccupationalOutlookHandbookstatesthat...
(Date:11/23/2009)...swire/--InasurveyofNewJerseyandPhiladelphiaregiona...2percentdonotbelieveanewhealthcarebillwouldlikelyr...esultsofthelatestsurveyconductedbytheAlloySilverst...ppedthelistat85percentasthebiggestnationalissue.Th...tocompaniesfromallpartsofNewJerseyandSoutheasternP...
(Date:11/23/2009)...nce Writings at Stevens Institute of Technology wi...t Wright, journalist and founder, Bloggingheads.tv...he Babbio Center for Technology Management, Room 1...he media., In his new book "The Evolution of God...ned for his popular works on evolutionary psycholo...
Breaking Medicine News(10 mins):Health News:RetireSafe Calls on Seniors to Grab their Bullhorns to Save Medicare from Rationed Care 2Health News:Tips to Improve Healthcare Customer Service Across All Generations 2Health News:Cortiva Institute To Host Workshop, Hands-On Opportunity for Prospective Students 2
...ncy-related blood pressure condition can pose seri...RIDAY, Oct. 17 (HealthDay News) -- Pregnant with h...minal pain and headaches until her symptoms worsen...is one of hundreds of women whose brush with preec...
...cademy of Ophthalmology hosts event October 24 ben... Sullivan headlines event, OKLAHOMA CITY, Oct. 17...e second annual "Eye Ball," benefiting the,Juvenil...Gary Story of Oklahoma City are the honorary chair...
...t. 17 American Well today announced that CEO,Roy ...product management;,and Michael Stollar, vice pres...s Blue Shield of Hawaii (HMSA), will provide a liv...t 10:00,a.m. PDT on October 23, 2008 at San Franci...
..., Calif., Oct. 17 Wyle is a key partner in,the wi...Center contract to,provide occupational health ser...year contract, valued at up to $24 million, is due...ealth physics,and respiratory protection., "We ar...
...sunderstand written screening tools, but ,talking,...17 (HealthDay News) -- Many patients misunderstand...answer before physical exams, a finding that calls...he American College of Surgeons, found that lower-...
...TON, Oct. 17 After a destructive,hurricane season... for,disasters, the American Public Health Associa...d ones are prepared for winter storms and any othe...make sure their emergency preparedness kits are st...
Other Medicine News:Health News:Research May Help Predict Preeclampsia 2Health News:Research May Help Predict Preeclampsia 3Health News:Research May Help Predict Preeclampsia 4Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 2Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 3Health News:American Well Systems CEO Roy Schoenberg to Present Live Public Demo of First Online Care Service at Health 2.0 Conference 2Health News:Wyle Key Part of Winning Team for Marshall Space Flight Center Occupational Health Services Contract 2Health News:Doctors Often Overestimate Patients' Health Literacy 2Health News:Check Your Emergency Preparedness Kits When You Set Your Clocks, Says American Public Health Association Campaign 2
(Date:11/23/2009)...re-FirstCall/--WoundManagementTechnologies,Inc.,(O...ialtymedicalproducts,announcedthatithasfileditQ320...gementbusinessupdatetoillustratethedevelopmentsdur...d33.5%to$102,926vs.Q32008salesof$77,084. , Sh...s.Q32008shareholderequityof$(321,257) , Total...
(Date:11/23/2009)...tCall/--CordBloodAmerica,Inc.(OTCBulletinBoard:CBA...y( http://www.cordblood-america.com )focusedonbrin...nsurancepolicy,tofamiliesnationwideandinternationa...thCEOandco-founderMatthewSchisslerisnowavailable. ...2875811 . ,, Intheinterview,Mr.Schisslerupdates...
(Date:11/23/2009)...-FirstCall/--RaptorPharmaceuticalCorp.("Raptor"ort...tationofclinicaltrialdataonNGX426,theCompany,soral...gonist,atthe12thInternationalConferenceontheMechan...-21inSanFrancisco.TheresultsofthestudyledbyMarkWal...nterforPainMedicineoftheUniversityofCaliforniaatSa...
Breaking Medicine Technology:Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 2Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 3Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 4Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 5Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 1Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 2Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health 28CDRH 29 4629 3CoAxia Inc Announces 2421 5M Series D Financing 4628 1CoAxia Inc Announces 2421 5M Series D Financing 4628 2CoAxia Inc Announces 2421 5M Series D Financing 4628 3Lilly Declares Third Quarter Dividend 49687 1
...e II study extension shows 68-73% of patients with... three years of treatment with oral FTY720,- New d...rain lesions - the injury caused by MS - thr...ating disease causing progressive disability, affe...g many young adults - FTY720 regulatory filings p...
... MEK inhibitor, RDEA119, demonstrates potential fo...nary Phase 1 results -, - Next generation MEK inh... half of 2008 -, SAN DIE...EA ) today announced that data was presented demon...okinetic profile of the Company,s,mitogen-activate...
Other Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 2Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 3Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 4
...s a second generation nucleic acid amplification t...ive detection and differentiation of rRNA from CT ...ven technologies including target capture (TC), Tr...Kinetic Assay (DKA). This is the same family of te...
One-Step Gonorrhea Antigen Test
...on Information System) is an open architecture sys...tform designed to communicate and manage patient d...in various ways, as NAVIS can connect not only to ...halmic diagnostic equipment of other manufacturers...
...state technology, this laser emit true continuous-...d-state technology offers unsurpassed reliability,...lity, compact size allows easy transportation betw...tine laser maintenance. The EasyFit Adapter conver...
Medicine Products: